Immunovant appoints new CEO and expands drug indications

By Bobby Samwell • Monday, April 21 15:19 • Permanent Link

Immunovant, Inc. (NASDAQ: IMVT) has announced significant changes to its leadership team and an expansion of its developmental initiatives with the addition of two new indications for its IMVT-1402 drug. Eric Venker, M.D., who currently serves as the President and COO of Roivant, has been appointed as the CEO of Immunovant, bringing with him over two decades of clinical practice and operational experience. This change follows the retirement of Pete Salzmann, M.D., from his role as CEO and Director of Immunovant.

The company has also seen a change in its CFO, with Tiago Girao taking over from Renee Barnett. Additionally, George Migausky has stepped down from the Immunovant board of directors, while Robert Susman and Jacob Bauer have joined the board.

Immunovant's latest developments include the expansion of IMVT-1402 into two new indications: Sjögren’s Disease (SJD) and Cutaneous Lupus Erythematosus (CLE). The company has received IND clearance for a potentially registrational program for IMVT-1402 in SJD, with the study expected to commence in the summer of 2025. Furthermore, a proof-of-concept study of IMVT-1402 has been initiated in CLE.

The company’s current cash balance provides a runway for the announced indications through the Graves’ Disease readout, expected in 2027. These strategic shifts are part of a broader transition, with Roivant taking on increased operational involvement and strategic oversight of Immunovant.

This move comes as Immunovant aims to build on its compelling efficacy data in clinical trials for its existing indications, while also advancing the IMVT-1402 program into a total of six indications.

Investors are invited to join Roivant’s live conference call and webcast at 8:00 a.m. EDT on Monday, April 21, 2025, to discuss these updates at Immunovant.

Sjögren’s Disease (SJD) is a chronic autoimmune disease characterized by severe dryness of the mouth and eyes, while Cutaneous Lupus Erythematosus (CLE) is a rare, chronic skin disease with a high unmet medical need.

Immunovant, Inc. is a clinical-stage immunology company dedicated to developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. The market has reacted to these announcements by moving the company's shares -5.3% to a price of $14.34. For the full picture, make sure to review Immunovant's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.